Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

ts as a potential alternative to currently available standard anthracycline drugs."

The PIX 301 EXTEND (Expanding the reach of antrhacyclines with piXanTronE in relapsed or refractory aggressive NHL Disease) trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

In the PIX 301 EXTEND trial 57% of the randomized patients were refractory to prior treatments with 50% of patients having failed three prior chemotherapy treatments. More than 70% of the patients on both arms were considered intermediate to high risk by the International Prognostic Index score (>=2). The median prior doxorubicin equivalent dose was approximately 300 mg/m2, the dose that is associated with six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy, the standard of care for first line therapy in this disease. Fifty-three percent of pixantrone patients received four or more cycles of therapy compared to a median of three cycles in the comparator arm. The median doxorubicin equivalent dose at the end of therapy was 513 mg/m2 (with a range of 115 mg/m2 to 1003mg/m2). Data from repeated evaluations of Left Ventricular Ejection Fraction ("LVEF") by MUGA (Multi Gated Acquisition Scan) scan demonstrated no consistent dose related decline as has been described for doxorubicin with median LVEF values at a baseline of 58% and at the end of treatment of 59%. Consistent across the primary and subgroup analyses, treatment with pixantrone resulted in superior clinical benefits over standard of car
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Proove Biosciences , the ... presenting research on the association between specific genes and ... Psychiatric and Mental Health Congress’ 27th Annual Scientific ... on the theme of ‘Embracing Change.’ Mental health, and ... landscape. From the challenges presented by the Affordable Care ...
(Date:9/23/2014)... San Jose, California (PRWEB) September 23, 2014 ... – Agricultural biotechnology is gaining steady popularity the ... sophisticated plant breeding techniques. Growth in the marketplace ... Genetically Modified (GM) crops in developing countries. Several ... 30% of under-nourished population, have already implemented genetically ...
(Date:9/23/2014)... This is a professional and ... Isopropanol (IPA) industry. The report provides a basic ... industry chain structure. Global market analysis and Chinese ... on history, developments, trends and competitive landscape of ... Chinese situation is also offered. , The report ...
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, its ... 280 nm wavelength range. This series joins Marktech’s current ... to 405nm. These new devices are suitable for applications ... Mark Campito, Marktech’s CEO states that “what makes this ... that we offer it in one of the largest ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 2Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Marktech Introduces its New Line of Deep UV Emitters 2
... Split Effective at Close of Business Today ... - VGNI Stock Symbol to Change to VRGE, PLANTATION, ... majority-owned subsidiary,of Viragen, Inc. (OTC Bulletin Board: VRAI), today announced that ... outstanding common stock,will become effective at the close of business today, ...
... 4, Dow AgroSciences LLC, a wholly owned subsidiary,of ... and Exelixis Plant Sciences, a,wholly owned subsidiary of ... the companies have signed a major research collaboration ... Dow AgroSciences,affiliate Agrigenetics Inc. The agreement is focused ...
... forum for the global pharma/biotech industries, Pharmaceutical Manufacturing and Biotechnology Middle ... ... DUBAI, United Arab Emirates, Sept. 4 The Middle East,market for pharmaceutical ... growth in double digits. The market,drivers are: -- Dubai is the ...
Cached Biology Technology:Viragen International to Reverse Split Its Common Stock 2Viragen International to Reverse Split Its Common Stock 3Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 3
(Date:9/23/2014)... National Institutes of Health will award funds to support ... Screening program to improve ways of predicting drug safety ... refine existing 3-D human tissue chips and combine them ... functions of the human body. Led by the National ... support 11 institutions at $17 million in 2014 with ...
(Date:9/23/2014)... announced today that the Company has secured $21 million ... be used to expand the Company,s cancer immunotherapy pipeline ... investor Yuan Capital led the round, with participation from ... Ventures, Suma Venture and Harbinger Venture Capital. , ... fully-human antibodies engineered to mimic the functions of a ...
(Date:9/23/2014)... are the same ones that were used 50 years ago. ... disease, which causes nearly 25 million people in the United ... best to take a deep breath. , But finding ... what works for one person doesn,t necessarily work for another, ... candidates often fail to mimic human responses costing tremendous ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3
... a great health threat, especially since routine smallpox ... treatment currently exists. In the February 1 issue ... and colleagues from Harvard Medical School propose a ... of signaling mediated by the smallpox growth factor ...
... research on prions, the infectious proteins behind "mad cow" disease ... prions in one species to infect other species depends on ... prion. Two studies on the topic appear in the 8 ... suggests that prions from one species rarely infect other species, ...
... tweaked to absorb more contaminants, researchers found that the ... results raised hopes that the plants might become a ... new research findings, published Feb. 1 in the journal ... of the Indian mustard plant, Brassica juncea, absorbed two ...
Cached Biology News:Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection 2Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Biology Products: